RxDoctor Payments Data

Michelle Apicella, PA

Physician Assistant · Brunswick, OHNPI 1316440878

Payments from drug & device makers

$8,037in general payments, 2019–2025

Across 129 payments — averaging $62.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$6K
  • AstraZeneca$510
  • Sanofi$403
  • Regeneron Healthcare Solutions, Inc.$347
  • United Therapeutics Corporation$303
  • GSK$231
  • plus $609 from 7 others

What the payments were for

  • Consulting fees$2,68833%
  • Travel & lodging$1,09814%
  • Food & beverage$4,06851%
  • Education$1842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,037 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio

Medicare billing

Part B allowed, 2024
$43,239
Medicare patients
227
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab20$73,689
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$59,540
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$47,697
Spiriva RespimatTiotropium Bromide49$37,620
Breo ElliptaFluticasone/Vilanterol73$32,242
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$30,432
Bevespi AerosphereGlycopyrrolate/Formoterol Fum57$27,965
Advair HfaFluticasone Propion/Salmeterol60$24,072
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$19,605
SymbicortBudesonide/Formoterol Fumarate42$13,816
DuleraMometasone/Formoterol35$13,643
Incruse ElliptaUmeclidinium Bromide18$10,142
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate44$5,464
Arnuity ElliptaFluticasone Furoate18$5,447
Albuterol Sulfate HfaAlbuterol Sulfate200$5,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$231$125,960205 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$510$101,321171 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$190$57,22573 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.

Other physician assistant in Brunswick

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →